A handful of small caps, including Sensei and PDS, jumped on Asco abstract data, with much more news to come.
A radionuclide deal between Lantheus and Noria mirrors that done by Novartis and Sofie, among others.
The second quarter brings updates for Scholar Rock, Alnylam and Dicerna, among others.
A focus on rare diseases and regulatory acceptance of cannabis make GW the subject of a $7.2bn buyout.
Competing folate receptor-targeting projects have recorded one failure after another, but Sutro scores a phase I win.
Adaptimmune and Allogene led numerous cell therapy companies higher over the Asco period, while Cytomx and Arvinas suffered the biggest losses.
An early look at data from the huge cancer conference boosts Allogene and Immunogen, while Arvinas and Cytomx suffer.
Celgene’s registrational Transcend NHL-001 study will be a big story at Ash, but the early focus falls on what has not been presented.